Arsenicals (Arsenic Compounds)

1.	Cullen, William R: 3 articles (02/2005 - 07/2002)
2.	Kitchin, Kirk T: 2 articles (01/2008 - 07/2002)
3.	Creus, Amadeu: 2 articles (12/2007 - 03/2004)
4.	O'Brien, Tom: 1 article (01/2008)
5.	Chen, Yan: 1 article (01/2008)
6.	Thomas, David J: 1 article (01/2008)
7.	Del Razo, Luz Maria: 1 article (01/2008)
8.	Soriano, Carolina: 1 article (12/2007)
9.	Marcos, Ricard: 1 article (12/2007)
10.	Gurr, Jia-Ran: 1 article (02/2007)

Related Diseases

1.	Acute Promyelocytic Leukemia 10/15/1999 - "Arsenic compounds have recently been shown to induce high rates of complete remission in patients with acute promyelocytic leukemia (APL). " 06/01/2001 - "PURPOSE: Arsenic compounds have been found to be effective in the treatment of acute promyelocytic leukemia through the downregulation of bcl-2 expression. " 01/01/2001 - "Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies." 08/15/2009 - "Differential cytotoxic effects of arsenic compounds in human acute promyelocytic leukemia cells." 01/01/2002 - "While some of the molecular activities of ATO are specific to acute promyelocytic leukemia, arsenicals also have a broad variety of antineoplastic properties that may be useful in combination therapy with agents that target specific molecular defects of Bcr-Abl-positive leukemias." Order ALL the reference details at left...
2.	Neoplasms (Cancer) 06/01/2001 - "CONCLUSIONS: Arsenic compounds (As2O3 and As2S3) can inhibit growth and induce apoptosis in human ovarian and cervical cancer cells at clinically achievable concentrations, indicating that As2O3 and As2S3 could be effective in the treatment of gynecological cancer." 10/15/2008 - "A large amount of evidence suggests that arsenicals act via oxidative stress in causing cancer in humans and experimental animals. " 08/01/2008 - "Little is known regarding the possible secondary cancers resulting from the long-term use of any of these arsenicals. " 01/01/2006 - "Although the arsenic compounds are now widely utilized in clinics in the treatment of various tumors, their effects on normal hematopoiesis do not seem to have been explored. " 06/01/2005 - "Arsenic compounds are also being used as cancer chemotherapeutic agents. " Order ALL the reference details at left...
3.	Leukemia 08/01/1981 - "Animal carcinogenicity studies involving exposure to various inorganic and organic arsenic compounds by different routes have been negative, with the possible exception of some preliminary data regarding lung cancer and leukemia. " 01/01/2002 - "While some of the molecular activities of ATO are specific to acute promyelocytic leukemia, arsenicals also have a broad variety of antineoplastic properties that may be useful in combination therapy with agents that target specific molecular defects of Bcr-Abl-positive leukemias." 08/01/2001 - "This paper focuses on the recent progress in defining the molecular mechanisms underlying APL pathogenesis and addresses how this new understanding has allowed the proposal and development of novel therapeutic strategies with compounds such as histone deacetylase inhibitors and inorganic arsenicals such as As2O3 which are currently being tested in murine leukemia models as well as in human APL patients. " 01/21/1998 - "Understanding the molecular basis of these differences in the effects of As2O3 and retinoic acid may guide the clinical use of arsenic compounds and provide insights into the management of leukemias that do not respond to retinoic acid." 12/01/2006 - "The development of new generations of orally bioavailable inorganic, as well as new organic, arsenic compounds with improved toxicity profiles may bolster the therapeutic application of arsenic derivatives in hematologic malignancies such as leukemia, multiple myeloma and myelodysplastic syndromes." Order ALL the reference details at left...
4.	Multiple Myeloma 11/01/2006 - "Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy." 11/01/2006 - "The use of arsenic compounds in the treatment of multiple myeloma (MM) is supported by the proposed mechanisms of action underlying the antitumor activity of arsenic and by preclinical studies showing antiproliferative and cytotoxic activities in cell culture and animal models. " 12/01/2006 - "The development of new generations of orally bioavailable inorganic, as well as new organic, arsenic compounds with improved toxicity profiles may bolster the therapeutic application of arsenic derivatives in hematologic malignancies such as leukemia, multiple myeloma and myelodysplastic syndromes." Order ALL the reference details at left...
5.	Poisoning 10/01/1992 - "[Therapy of exogenous poisoning due to arsenicals]" 07/01/1979 - "[An episode of subacute poisoning by inorganic arsenic compounds (author's transl)]" 07/01/1973 - "Effect of pharmacologic or surgical conditioning upon intoxication with arsenicals." 11/11/1965 - "[Poisoning by arsenicals in agriculture]" 01/01/1957 - "[Poisoning with arsenic compounds in fruits.]" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Arsenic
2.	Aligeron (AS 2)
3.	arsenic trioxide (Trisenox)
4.	Ions
5.	arsenic trisulfide
6.	Glutaminase
7.	oxophenylarsine (phenylarsine oxide)
8.	arsenite
9.	arsenic acid (arsenate)
10.	Carcinogens

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Chinese Traditional Medicine (Traditional Chinese Medicine)
3.	Investigational Therapies (Experimental Therapy)
4.	East Asian Traditional Medicine (Oriental Medicine)
5.	Oral Administration

Best Treatments:
Research Summary Report
on Acute Promyelocytic Leukemia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 388 Outcomes
Top 200 Key Drugs and Biologics
Top 37 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>